Physician profile
John P Diaz
NPI 1578719167
$87,397.51
in general payments reported to CMS, 2019-2025
28 companies · $3,436 in 2025
The $3,436 reported for 2025 was more than what 83% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $22K · 2021: $12K · 2022: $13K · 2023: $4,069 · 2024: $13K · 2025: $3,436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,492 · Travel and Lodging: $5,375 · Consulting Fee: $4,480 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,500 · Education: $2,100 · Gift: $49.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,491.65 |
| Travel and Lodging | $5,374.51 |
| Consulting Fee | $4,480.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,500.00 |
| Education | $2,099.99 |
| Gift | $49.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $48,754.88 | 2019-2024 | |
| Intuitive Surgical, INC. | $14,854.86 | 2019-2025 | Da Vinci Surgical System |
| Merck Sharp & Dohme LLC | $7,655.49 | 2020-2024 | Keytruda, Lynparza |
| Medtronic, INC. | $3,142.14 | 2022-2024 | |
| Eisai INC. | $2,932.77 | 2020-2022 | |
| Glaxosmithkline, LLC. | $2,130.36 | 2019-2023 | Jemperli, Zejula, Trelegy Ellipta |
| Seagen INC. | $1,933.15 | 2022-2023 | Tivdak |
| Karyopharm Therapeutics INC. | $1,672.00 | 2024 | Xpovio |
| Linvatec Corporation | $1,000.00 | 2021 | |
| Conmed Corporation | $896.99 | 2019-2025 | Airseal, Visiclear |
| Abbvie INC. | $557.51 | 2019-2024 | |
| Ethicon US, LLC | $477.09 | 2019-2025 | Endopath Xcel, Ethicon, Vistaseal |
| Hologic Sales and Service, LLC | $426.61 | 2021-2025 | Myosure Tissue Removal Device, Thinprep 2000 Processor, Aptima |
| On Target Laboratories, INC | $160.23 | 2025 | Cytalux |
| Astellas Pharma US INC | $135.25 | 2023 | Veozah |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biom'Up France Sas | $132.09 | 2021 | |
| Medtronic Vascular, INC. | $129.75 | 2019 | |
| Covidien LP | $100.00 | 2019 | |
| Genmab U.S., INC. | $94.08 | 2023 | Tivdak |
| Procept Biorobotics Corporation | $82.35 | 2024 | Aquabeam System |
| Sumitomo Pharma America, INC. | $52.94 | 2023 | Myfembree |
| Myriad Genetic Laboratories, INC. | $27.03 | 2023 | Myrisk |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.37 | 2023 | Xifaxan |
| Amryt Pharma Holdings LTD | $16.87 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.70 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.